scispace - formally typeset
K

Klaus P Machold

Researcher at Medical University of Vienna

Publications -  108
Citations -  10209

Klaus P Machold is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 46, co-authored 105 publications receiving 9542 citations. Previous affiliations of Klaus P Machold include Ludwig Maximilian University of Munich & University of Vienna.

Papers
More filters
Journal ArticleDOI

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

TL;DR: A purely clinical score is a valid measure of disease activity and will have its greatest merits in clinical practice rather than research, where APRs are usually always available.
Journal ArticleDOI

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

TL;DR: 12 key recommendations for the management of early arthritis or early rheumatoid arthritis were developed, based on evidence in the literature and expert consensus, in accordance with EULAR's "standardised operating procedures".
Journal ArticleDOI

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis

TL;DR: There is a window of opportunity for highly successful treatment of RA in the first year, and especially within the first 3 months of therapy, indicating that early diagnosis and therapy may be the crucial step in achieving optimal control of disease progression and prognosis in RA.
Journal ArticleDOI

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial

TL;DR: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment, however, HCST conferred a significant long-term event-free survival benefit.